Status:
UNKNOWN
Effectiveness of Oral Boldo in Women With Overactive Bladder
Lead Sponsor:
Universidad de Valparaiso
Collaborating Sponsors:
Uro Medical Corporation
Conditions:
Urinary Bladder, Overactive
Eligibility:
FEMALE
18-60 years
Phase:
PHASE1
Brief Summary
The objective of this clinical trial is to know if boldo oral powder capsules works well in the management of urinary symptoms in women with overactive bladder. The main questions it aims to answer ar...
Detailed Description
10 women over 18 years of age who meet the selectivity criteria will be recruited under written informed consent, previously approved by the competent ethics committee. Patients will be diagnosed with...
Eligibility Criteria
Inclusion
- Adult patients with urinary urgency, frequency, nocturia, with or without urgency urinary incontinence.
Exclusion
- Excessive fluid intake. Use of diuretics. Neurological diseases or cognitive impairment (e.g., stroke, multiple sclerosis, spinal cord injury), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTI), gross hematuria, previous pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate), pelvic radiation, female patient with significant prolapse (GIII and IV), pelvic floor disorders (e.g., spasticity of the pelvic floor muscles, pain or any pathology that could appear overactive bladder masking other diagnoses, glaucoma, drug or supplement allergy.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06162065
Start Date
November 1 2023
End Date
March 30 2024
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clínica Uromed
Santiago, Santiago Metropolitan, Chile